IDEXX Laboratories beats first quarter 2026 estimates with 11% organic growth in CAG diagnostics and raises full-year guidance.

IDEXX Laboratories reported first quarter 2026 revenue of $1.141 billion, up 14% as reported and 11% on an organic basis, beating estimates. Earnings per share were $3.47, an increase of 17% over the prior year and also ahead of expectations. Following the strong results, the company raised its full-year 2026 revenue and EPS guidance.

Key Highlights

• Companion Animal Group (CAG) Diagnostics recurring revenue grew 11% organically, exceeding the high end of analyst expectations.
• Full-year 2026 guidance was increased, with the revenue outlook raised to a range of $4,675 million - $4,760 million and the EPS outlook raised to $14.45 - $14.90.
• IDEXX VetLab consumables revenue grew 15% organically, supported by a 12% year-over-year expansion of the global premium instrument installed base.